Skip to main content
Top
Published in: Archives of Osteoporosis 1/2019

01-12-2019 | Bisphosphonate | Original Article

Glucocorticoid-induced osteoporosis preventive care in rheumatology patients

Authors: G. Koller, S. Katz, T. L. Charrois, C. Ye

Published in: Archives of Osteoporosis | Issue 1/2019

Login to get access

Abstract

Summary

Glucocorticoid-induced osteoporosis (GIOP) is common in patients prescribed with long-term glucocorticoids. Guidelines suggest patients receiving moderate-dose glucocorticoid therapy receive GIOP preventive care. Previous studies have shown preventive care rates are not optimal. We look at GIOP preventive care rates in rheumatology patients and predictors of various components of care.

Purpose

Glucocorticoid-induced osteoporosis (GIOP) is a common concern in patients prescribed with long-term glucocorticoids. Studies have shown GIOP preventive care is not provided optimally in the general population; however, little is published on GIOP preventive care among patients with rheumatic disease. The objective of this study is to determine the proportion of rheumatology patients who received GIOP preventive care.

Methods

A population-based retrospective quality assurance study of adults seen at the University of Alberta Rheumatology Clinic was performed using the electronic outpatient medical record. Records of adult patients prescribed with prednisone from January 1st to December 31st, 2016 by a rheumatologist were initially included for review. Those who had been prescribed ≥ 7.5 mg/day for ≥ 3 months were assessed for concurrent GIOP preventive care.

Results

A total of 745 discreet courses of prednisone were prescribed in 433 patients with 113 meeting the above inclusion criteria. Following the prednisone prescription, 79% were taking vitamin D, 86% were taking calcium, and 50% were prescribed with osteoporosis pharmacotherapy. Twenty-five percent of patients had DXA imaging ordered by the rheumatologist within the first 6 months; of these, 86% of patients completed the DXA.

Conclusions

Overall, our study shows that patients under the care of rheumatologists receive better GIOP preventative care than previously reported care in the general population. However, there is still room for improvement. In particular, men, younger patients, and rural patients seem to be at the most at risk of not receiving optimal GIOP prevention.
Literature
1.
go back to reference Seror R, Dougados M, Gossec L (2009) Glucocorticoid sparing effect of tumour necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice. Clin Exp Rheumatol 27:807–813PubMed Seror R, Dougados M, Gossec L (2009) Glucocorticoid sparing effect of tumour necrosis factor alpha inhibitors in rheumatoid arthritis in real life practice. Clin Exp Rheumatol 27:807–813PubMed
2.
go back to reference Fortunet C, Pers YM, Lambert J, Godfrin-Valnet M, Constant E, Devilliers H, Gaudin P, Jorgensen C, Prades BP, Wendling D, Maillefert JF (2014) Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. Rheumatol (United Kingdom) 54:672–677. https://doi.org/10.1093/rheumatology/keu339 CrossRef Fortunet C, Pers YM, Lambert J, Godfrin-Valnet M, Constant E, Devilliers H, Gaudin P, Jorgensen C, Prades BP, Wendling D, Maillefert JF (2014) Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice. Rheumatol (United Kingdom) 54:672–677. https://​doi.​org/​10.​1093/​rheumatology/​keu339 CrossRef
3.
go back to reference Alten R, Nüßlein H, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Pavelka K, Chartier M, Poncet C, Rauch C, Elbez Y, le Bars M (2016) Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study. RMD Open 2:e000228. https://doi.org/10.1136/rmdopen-2015-000228 CrossRefPubMedPubMedCentral Alten R, Nüßlein H, Galeazzi M, Lorenz HM, Nurmohamed MT, Bensen WG, Burmester GR, Peter HH, Pavelka K, Chartier M, Poncet C, Rauch C, Elbez Y, le Bars M (2016) Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study. RMD Open 2:e000228. https://​doi.​org/​10.​1136/​rmdopen-2015-000228 CrossRefPubMedPubMedCentral
5.
go back to reference LoCascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, Tartarotti D, DellaRocca C (1990) Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8:39–51CrossRef LoCascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, Tartarotti D, DellaRocca C (1990) Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8:39–51CrossRef
11.
go back to reference Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD, for the Scientific Advisory Council of Osteoporosis Canada (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Cmaj 182:1864–1873. https://doi.org/10.1503/cmaj.100771 CrossRefPubMedPubMedCentral Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD, for the Scientific Advisory Council of Osteoporosis Canada (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Cmaj 182:1864–1873. https://​doi.​org/​10.​1503/​cmaj.​100771 CrossRefPubMedPubMedCentral
13.
go back to reference Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Byun Robinson A, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T (2017) 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 69:1095–1110. https://doi.org/10.1002/acr.23279 CrossRef Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Byun Robinson A, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T (2017) 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 69:1095–1110. https://​doi.​org/​10.​1002/​acr.​23279 CrossRef
16.
go back to reference Albaum JM, Youn S, Levesque LE, Gershon AS, Cadarette SM (2014) Osteoporosis management among chronic glucocorticoid users: a systematic review. J Popul Ther Clin Pharmacol 21:e486–e504PubMed Albaum JM, Youn S, Levesque LE, Gershon AS, Cadarette SM (2014) Osteoporosis management among chronic glucocorticoid users: a systematic review. J Popul Ther Clin Pharmacol 21:e486–e504PubMed
18.
go back to reference Overman RA, Toliver JC, Yeh J-Y, Gourlay ML, Deal CL (2014) United States adults meeting 2010 American College of Rheumatology criteria for treatment and prevention of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 66:1644–1652. https://doi.org/10.1002/acr.22346 CrossRef Overman RA, Toliver JC, Yeh J-Y, Gourlay ML, Deal CL (2014) United States adults meeting 2010 American College of Rheumatology criteria for treatment and prevention of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 66:1644–1652. https://​doi.​org/​10.​1002/​acr.​22346 CrossRef
19.
Metadata
Title
Glucocorticoid-induced osteoporosis preventive care in rheumatology patients
Authors
G. Koller
S. Katz
T. L. Charrois
C. Ye
Publication date
01-12-2019
Publisher
Springer London
Published in
Archives of Osteoporosis / Issue 1/2019
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-019-0570-9

Other articles of this Issue 1/2019

Archives of Osteoporosis 1/2019 Go to the issue